European Crohn’s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease

Torres, Joana; Ellul, Pierre; Langhorst, Jost; Mikocka‐Walus, Antonina; Acosta, Manuel Barreiro‐de; Basnayake, Chamara; Ding, Nik Sheng; Gilardi, Daniela; Κατσάνος, Κωνσταντίνος; Moser, Gabriele; Opheim, Randi; Palmela, Carolina; Pellino, Gianluca; Marel, Sander van der; Vavricka, Stephan R.

doi:10.1093/ecco-jcc/jjz051

Cited by 88 publications

(83 citation statements)

References 210 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IBD treatment with these drugs is inherently burdened by some degree of immunosuppression and by a greater likelihood of infections, although there does not seem to be a strong association between the occurrence of infections and biological drug dose 12,13 . This notwithstanding, patients with IBD are often concerned regarding the potential for the occurrence of immunosuppression‐related events, and in general, in patients with IBD, the occurrence of stressor events may represent a trigger for disease relapse 14 …”

Section: Research Lettermentioning

confidence: 99%

Concerns related to COVID‐19 pandemic among patients with inflammatory bowel disease and its influence on patient management

Bodini

Demarzo

Casagrande

et al. 2020

Eur J Clin Investigation

View full text Add to dashboard Cite

Section: Research Lettermentioning

confidence: 99%

Concerns related to COVID‐19 pandemic among patients with inflammatory bowel disease and its influence on patient management

Bodini

Demarzo

Casagrande

et al. 2020

Eur J Clin Investigation

View full text Add to dashboard Cite

“…One of the most studied conditions in gastroenterology field, IBD is a set of chronic disorders that affects the digestive tract and includes Crohn's disease (CD) and ulcerative colitis (UC)[ 11 ]. Although the mechanisms involved in IBD genesis are broadly studied, they are not well understood and may include genetic, immune, and environmental interactions[ 12 ].…”

Section: Extragastric Manifestationsmentioning

confidence: 99%

Helicobacter pylori infection: Beyond gastric manifestations

Santos

Brito

Silva

et al. 2020

WJG

View full text Add to dashboard Cite

Helicobacter pylori ( H. pylori ) is a bacterium that infects more than a half of world’s population. Although it is mainly related to the development of gastroduodenal diseases, several studies have shown that such infection may also influence the development and severity of various extragastric diseases. According to the current evidence, whereas this bacterium is a risk factor for some of these manifestations, it might play a protective role in other pathological conditions. In that context, when considered the gastrointestinal tract, H. pylori positivity have been related to Inflammatory Bowel Disease, Gastroesophageal Reflux Disease, Non-Alcoholic Fatty Liver Disease, Hepatic Carcinoma, Cholelithiasis, and Cholecystitis. Moreover, lower serum levels of iron and vitamin B12 have been found in patients with H. pylori infection, leading to the emergence of anemias in a portion of them. With regards to neurological manifestations, a growing number of studies have associated that bacterium with multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and Guillain-Barré syndrome. Interestingly, the risk of developing cardiovascular disorders, such as atherosclerosis, is also influenced by the infection. Besides that, the H. pylori -associated inflammation may also lead to increased insulin resistance, leading to a higher risk of diabetes mellitus among infected individuals. Finally, the occurrence of dermatological and ophthalmic disorders have also been related to that microorganism. In this sense, this minireview aims to gather the main studies associating H. pylori infection with extragastric conditions, and also to explore the main mechanisms that may explain the role of H. pylori in those diseases.

show abstract

“…The European Crohn's and Colitis Organization (ECCO) recently published a Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease and provided clinical guidance based on the current available evidence. 99 They outlined that curcumin, in combination with 5-ASA, may be effective in inducing remission in mild-to-moderate UC as well as potentially being effective as a complementary maintenance therapy in UC. They concluded that omega-3 fatty acids may be beneficial in maintaining remission in Crohn's disease; however, study quality and heterogeneity of trials limit these findings.…”

Section: Clinical Guidelinesmentioning

confidence: 99%

Complementary and alternative medications in the management of inflammatory bowel disease

Picardo

Altuwaijri

Devlin

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

The use of complementary and alternative medications (CAM), products, and therapies not considered to be part of conventional medicine is common among patients with inflammatory bowel disease (IBD). Patients often turn to these therapies as they are considered natural and safe, with significant benefit reported beyond disease control. There is emerging evidence that some of these therapies may have anti-inflammatory activity; however, robust evidence for their efficacy in modulating disease activity is currently lacking. Patients often avoid discussing the use of CAM with their physicians, which may lead to drug interactions and/or reduced adherence with conventional therapy. It is important for physicians to be aware of the commonly used CAM and current evidence behind these therapies in order to better counsel their patients about their use in the management of IBD. This narrative review provides an overview of the evidence of the more commonly used CAM in patients with IBD.

show abstract

European Crohn’s and Colitis Organisation Topical Review on Complementary Medicine and Psychotherapy in Inflammatory Bowel Disease

Cited by 88 publications

References 210 publications

Concerns related to COVID‐19 pandemic among patients with inflammatory bowel disease and its influence on patient management

Concerns related to COVID‐19 pandemic among patients with inflammatory bowel disease and its influence on patient management

Helicobacter pylori infection: Beyond gastric manifestations

Complementary and alternative medications in the management of inflammatory bowel disease

Contact Info

Product

Resources

About